Antitumor activity of BRAF inhibitor vemurafenib in preclinical models of BRAF-mutant colorectal cancer.

No abstract is available for this paper.

• Publication year

  2012

• Venue

  Cancer Research

• Publication date

  2012-02-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1158/0008-5472.CAN-11-2941PMID 22180495
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Optimizing targeted therapeutic development: Analysis of a colorectal cancer patient population with the BRAFV600E mutation

  2011cited by this paper
• BRAF mutation is a powerful prognostic factor in advanced and recurrent colorectal cancer

  2011cited by this paper
• Improved survival with vemurafenib in melanoma with BRAF V600E mutation.

  2011cited by this paper
• The BRAFT1799A mutation confers sensitivity of thyroid cancer cells to the BRAFV600E inhibitor PLX4032 (RG7204).

  2011cited by this paper
• Cetuximab plus irinotecan, fluorouracil, and leucovorin as first-line treatment for metastatic colorectal cancer: updated analysis of overall survival according to tumor KRAS and BRAF mutation status.

  2011cited by this paper
• BRIM-2: An open-label, multicenter phase II study of vemurafenib in previously treated patients with BRAF V600E mutation-positive metastatic melanoma.

  2011cited by this paper
• Improved classification of breast cancer by analysis of genetic alterations and gene expression profiling

  2011cited by this paper
• Selective and Potent Raf Inhibitors Paradoxically Stimulate Normal Cell Proliferation and Tumor Growth

  2010cited by this paper
• Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma

  2010cited by this paper
• RAF inhibitors transactivate RAF dimers and ERK signaling in cells with wild-type BRAF

  2010cited by this paper
• PLX4032, a selective BRAFV600E kinase inhibitor, activates the ERK pathway and enhances cell migration and proliferation of BRAFWT melanoma cells

  2010cited by this paper
• RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth

  2010cited by this paper
• MK-2206, an Allosteric Akt Inhibitor, Enhances Antitumor Efficacy by Standard Chemotherapeutic Agents or Molecular Targeted Drugs In vitro and In vivo

  2010cited by this paper
• Kinase-Dead BRAF and Oncogenic RAS Cooperate to Drive Tumor Progression through CRAF

  2010cited by this paper
• Pharmacodynamic characterization of the efficacy signals due to selective BRAF inhibition with PLX4032 in malignant melanoma.

  2010cited by this paper
• PLX4032, a potent inhibitor of the B‐Raf V600E oncogene, selectively inhibits V600E‐positive melanomas

  2010cited by this paper
• Predictors of competing mortality in advanced head and neck cancer.

  2010cited by this paper
• Activated Phosphoinositide 3-Kinase/AKT Signaling Confers Resistance to Trastuzumab but not Lapatinib

  2010cited by this paper
• Inhibition of mutated, activated BRAF in metastatic melanoma.

  2010cited by this paper
• RG7204 (PLX4032), a selective BRAFV600E inhibitor, displays potent antitumor activity in preclinical melanoma models.

  2010cited by this paper
• PLX4032 in metastatic colorectal cancer patients with mutant BRAF tumors.

  2010cited by this paper
• RG7204 (PLX4032), a Selective BRAFV600E Inhibitor, Displays Potent Antitumor Activity in Preclinical Melanoma Models

  2010cited by this paper
• Cytostatic activity of adenosine triphosphate-competitive kinase inhibitors in BRAF mutant thyroid carcinoma cells.

  2009cited by this paper
• Biomarkers Predicting Clinical Outcome of Epidermal Growth Factor Receptor–Targeted Therapy in Metastatic Colorectal Cancer

  2009cited by this paper
• Chemotherapy, bevacizumab, and cetuximab in metastatic colorectal cancer.

  2009cited by this paper
• KRAS codon 61, 146 and BRAF mutations predict resistance to cetuximab plus irinotecan in KRAS codon 12 and 13 wild-type metastatic colorectal cancer

  2009cited by this paper
• In vivo activity of novel capecitabine regimens alone and with bevacizumab and oxaliplatin in colorectal cancer xenograft models

  2009cited by this paper
• Targeting the Raf/MEK/ERK pathway with small-molecule inhibitors.

  2008cited by this paper
• Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer.

  2008cited by this paper
• BRAF Silencing by Short Hairpin RNA or Chemical Blockade by PLX4032 Leads to Different Responses in Melanoma and Thyroid Carcinoma Cells

  2008cited by this paper
• Therapeutic strategies for inhibiting oncogenic BRAF signaling.

  2008cited by this paper
• Antitumor activity of HER1/EGFR tyrosine kinase inhibitor erlotinib, alone and in combination with CPT-11 (irinotecan) in human colorectal cancer xenograft models

  2007cited by this paper
• Roles of the Raf/MEK/ERK pathway in cell growth, malignant transformation and drug resistance.

  2007cited by this paper
• A functional genetic approach identifies the PI3K pathway as a major determinant of trastuzumab resistance in breast cancer.

  2007cited by this paper
• A negative feedback signaling network underlies oncogene-induced senescence.

  2006cited by this paper
• Mutation of the PIK3CA oncogene in human cancers

  2006cited by this paper
• Regulation of Raf-1 by direct feedback phosphorylation.

  2005cited by this paper
• Functional analysis of PIK3CA gene mutations in human colorectal cancer.

  2005cited by this paper
• Guilty as charged: B-RAF is a human oncogene.

  2004cited by this paper
• Targeting the mitogen-activated protein kinase cascade to treat cancer

  2004cited by this paper
• Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF.

  2004cited by this paper
• High Frequency of Mutations of the PIK3CA Gene in Human Cancers

  2004cited by this paper
• Antitumor activity of erlotinib (OSI-774, Tarceva) alone or in combination in human non-small cell lung cancer tumor xenograft models

  2004cited by this paper
• Mutations of the BRAF gene in human cancer

  2002cited by this paper
• Tumorigenesis: RAF/RAS oncogenes and mismatch-repair status

  2002cited by this paper
• Paradoxical activation of Raf by a novel Raf inhibitor.

  1999cited by this paper
• Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays.

  1983cited by this paper

• The paradigm shift: re-evaluating preclinical animal models for colorectal cancer in the precision medicine era

  2026cites this paper
• Co-targeting SRC overcomes resistance to BRAF inhibitors in colorectal cancer

  2025cites this paper
• BRAFV600E mutant metastatic colorectal cancer: Current advances in personalized treatment and future perspectives.

  2025cites this paper
• Concurrent inhibition of ICMT and RAF/MEK suppresses RAC1P29S-driven MAPKi resistance in BRAFV600E melanoma by regulating TAZ activity

  2025cites this paper
• New antiproliferative 1,3,4-oxadiazole/benzimidazole derivatives: Design, synthesis, and biological evaluation as dual EGFR and BRAFV600E inhibitors.

  2025cites this paper
• PROTACs improve selectivity for targeted proteins

  2025cites this paper
• An Evolving Landscape: New Therapies for Metastatic Colorectal Cancer.

  2024cites this paper
• Signaling pathways in colorectal cancer: implications for the target therapies

  2024cites this paper
• Mcl-1 mediates intrinsic resistance to RAF inhibitors in mutant BRAF papillary thyroid carcinoma

  2024cites this paper
• MOGAT3-mediated DAG accumulation drives acquired resistance to anti-BRAF/anti-EGFR therapy in BRAFV600E-mutant metastatic colorectal cancer

  2024cites this paper
• Targeting CD20-expressing malignant melanoma cells augments BRAF inhibitor killing.

  2024cites this paper
• A reversible SRC-relayed COX2 inflammatory program drives resistance to BRAF and EGFR inhibition in BRAFV600E colorectal tumors

  2023cites this paper
• Early Combined SHP2 Targeting Reverses the Therapeutic Resistance of Vemurafenib in Thyroid Cancer

  2023cites this paper
• MUC1-C is necessary for SHP2 activation and BRAF inhibitor resistance in BRAF(V600E) mutant colorectal cancer.

  2023cites this paper
• Antitumor Efficacy of Dual Blockade with Encorafenib + Cetuximab in Combination with Chemotherapy in Human BRAFV600E-Mutant Colorectal Cancer

  2023cites this paper
• Successes and challenges in modeling heterogeneous BRAFV600E mutated central nervous system neoplasms

  2023cites this paper
• Ezrin Inhibition Overcomes Acquired Resistance to Vemurafenib in BRAFV600E-Mutated Colon Cancer and Melanoma Cells In Vitro

  2023cites this paper
• A comprehensive tool for tumor precision medicine with pharmaco-omics data analysis

  2023cites this paper
• Inhibiting BRAF/EGFR/MEK suppresses cancer stemness and drug resistance of primary colorectal cancer cells

  2023cites this paper
• CSCO guidelines for metastatic colorectal cancer: personalized medicine in clinical practice

  2023cites this paper
• Recent and Future Strategies to Overcome Resistance to Targeted Therapies and Immunotherapies in Metastatic Colorectal Cancer

  2022cites this paper
• Emerging actionable targets to treat therapy-resistant colorectal cancers

  2022cites this paper
• Therapeutic Targeting of Cancer Stem Cells Prevents Resistance of Colorectal Cancer Cells to MEK Inhibition.

  2022cites this paper
• Treatment of Advanced BRAF-Mutated Colorectal Cancer: Where We Are and Where We Are Going.

  2022cites this paper
• A reversible SRC-relayed COX2-inflammatory program drives therapeutic resistance in BRAFV600E colorectal tumors

  2022cites this paper
• The Therapeutic Potential of MAPK/ERK Inhibitors in the Treatment of Colorectal Cancer.

  2021cites this paper
• DBPOM: a comprehensive database of pharmaco-omics for cancer precision medicine

  2021cites this paper
• Molecular pathways, targeted therapies and proteomic investigations of colorectal cancer.

  2021cites this paper
• Nephrotoxicity of the BRAF-kinase inhibitor Vemurafenib is driven by off-target Ferrochelatase inhibition

  2021cites this paper
• Kidney toxicity of the BRAF-kinase inhibitor vemurafenib is driven by off-target ferrochelatase inhibition.

  2021cites this paper
• Ras Family of Small GTPases in CRC: New Perspectives for Overcoming Drug Resistance

  2021cites this paper
• The Sphingosine Kinase 2 Inhibitor ABC294640 Restores the Sensitivity of BRAFV600E Mutant Colon Cancer Cells to Vemurafenib by Reducing AKT-Mediated Expression of Nucleophosmin and Translationally-Controlled Tumour Protein

  2021cites this paper
• Some Important Targets For Development Of Anticancer Drugs

  2020cites this paper
• BRAF and KRAS mutations in metastatic colorectal cancer: future perspectives for personalized therapy

  2020cites this paper
• BRAF paradox breakers PLX8394, PLX7904 are more effective against BRAFV600Ε CRC cells compared with the BRAF inhibitor PLX4720 and shown by detailed pathway analysis.

  2020cites this paper
• BRAF Mutation in Colorectal Cancers: From Prognostic Marker to Targetable Mutation

  2020cites this paper
• Precision Medicine in Metastatic Colorectal Cancer—Finding and Hitting the Right Targets

  2020influential citation
• New advances in the clinical management of RAS and BRAF mutant colorectal cancer patients

  2020cites this paper
• Randomized Trial of Irinotecan and Cetuximab With or Without Vemurafenib in BRAF-Mutant Metastatic Colorectal Cancer (SWOG S1406).

  2020cites this paper
• The meiosis-specific cohesin component stromal antigen 3 promotes cell migration and chemotherapeutic resistance in colorectal cancer.

  2020cites this paper
• Antitumor Effects of Pan-RAF Inhibitor LY3009120 Against Lung Cancer Cells Harboring Oncogenic BRAF Mutation

  2020cites this paper
• Prevalence of class I–III BRAF mutations among 114,662 cancer patients in a large genomic database

  2020cites this paper
• Contemporary treatment approaches for metastatic colorectal cancer driven by BRAF V600 mutations

  2020cites this paper
• Encorafenib, binimetinib and cetuximab combined therapy for patients with BRAFV600E mutant metastatic colorectal cancer.

  2020cites this paper
• Assessing the translational value of pre-clinical studies for clinical response rate in oncology: an exploratory investigation of 42 FDA-approved small-molecule targeted anticancer drugs

  2020cites this paper
• Innovative trial design in precision oncology.

  2020cites this paper
• Treatment options in BRAF-mutant metastatic colorectal cancer.

  2020cites this paper
• Comprehensive review of targeted therapy for colorectal cancer

  2020cites this paper
• Synergistic Inhibition of Kinase Pathways Overcomes Resistance of Colorectal Cancer Spheroids to Cyclic Targeted Therapies.

  2019cites this paper
• Advances in the therapy of BRAFV600E metastatic colorectal cancer

  2019cites this paper
• Mapping phospho-catalytic dependencies of therapy-resistant tumours reveals actionable vulnerabilities

  2019cites this paper
• Identifying the ErbB/MAPK Signaling Cascade as a Therapeutic Target in Canine Bladder Cancer

  2019cites this paper
• DPS-2: A Novel Dual MEK/ERK and PI3K/AKT Pathway Inhibitor with Powerful Ex Vivo and In Vivo Anticancer Properties

  2019cites this paper
• Induced cross-resistance of BRAFV600E melanoma cells to standard chemotherapeutic dacarbazine after chronic PLX4032 treatment

  2019cites this paper
• Melatonin synergizes BRAF-targeting agent vemurafenib in melanoma treatment by inhibiting iNOS/hTERT signaling and cancer-stem cell traits

  2019cites this paper
• BRAF-Mutated Colorectal Cancer: Clinical and Molecular Insights

  2019cites this paper
• BRAF Mutation and Its Importance in Colorectal Cancer

  2019cites this paper
• Title Report on the use of non-clinical studies in the regulatoryevaluation of oncology drugs

  2019cites this paper
• Análise da responsividade de células de câncer colorretal ao vemurafenibe e influência em proteínas fosfatases e vias de sinalização do TGF beta e Notch1

  2019cites this paper
• The Development of Novel Apurinic/Aprymidinic Endonuclease/Redox-factor 1 Inhibitors for the Treatment of Human Melanoma

  2019cites this paper
• BRAF-mutant colorectal cancer, a different breed evolving

  2018cites this paper
• Colon Cancer , Version 2 . 2018 Featured Updates to the NCCN Guidelines

  2018cites this paper
• EV20‐mediated delivery of cytotoxic auristatin MMAF exhibits potent therapeutic efficacy in cutaneous melanoma

  2018cites this paper
• Signal transducer and activator of transcription 3 inhibition enhances vemurafenib sensitivity in colon cancers harboring the BRAFV600E mutation

  2018cites this paper
• Cyclical Treatment of Colorectal Tumor Spheroids Induces Resistance to MEK Inhibitors

  2018cites this paper
• Development of small-molecule therapeutics and strategies for targeting RAF kinase in BRAF-mutant colorectal cancer

  2018cites this paper
• Type II RAF inhibitor causes superior ERK pathway suppression compared to type I RAF inhibitor in cells expressing different BRAF mutant types recurrently found in lung cancer

  2018cites this paper
• EV 20-mediated delivery of cytotoxic auristatin MMAF exhibits potent therapeutic e ffi cacy in cutaneous melanoma

  2018cites this paper
• BRAF and EGFR inhibitors synergize to increase cytotoxic effects and decrease stem cell capacities in BRAF(V600E)-mutant colorectal cancer cells

  2018influential citation
• miR-550a-3-5p acts as a tumor suppressor and reverses BRAF inhibitor resistance through the direct targeting of YAP

  2018cites this paper
• The Art of War and oncology: applying the principles of strategy and tactics to greater effect in the era of targeted therapy.

  2018cites this paper
• NCCN Guidelines Insights: Colon Cancer, Version 2.2018.

  2018cites this paper
• Resistance of Colorectal Tumors to Anti-EGFR Antibodies

  2018cites this paper
• Emerging treatment options for BRAF-mutant colorectal cancer

  2018cites this paper
• Establishment of a novel cell line from a rare human duodenal poorly differentiated neuroendocrine carcinoma

  2018cites this paper
• BRAF and MEK Inhibitors: Use and Resistance in BRAF-Mutated Cancers

  2018cites this paper
• Molecular Markers and Mutational Analysis

  2018cites this paper
• BRAF mutant colorectal cancer: prognosis, treatment, and new perspectives

  2017cites this paper
• Vemurafenib Limits Influenza A Virus Propagation by Targeting Multiple Signaling Pathways

  2017cites this paper
• Molecular Testing in Colorectal Cancer

  2017cites this paper
• Recent Advances in Targeting the EGFR Signaling Pathway for the Treatment of Metastatic Colorectal Cancer

  2017cites this paper
• Metastatic Hepatic Angiosarcoma and BRAF Inhibitor Therapy

  2017cites this paper
• Present and future of metastatic colorectal cancer treatment: A review of new candidate targets

  2017cites this paper
• Molecular Landscape and Treatment Options for Patients with Metastatic Colorectal Cancer

  2017cites this paper
• Complementary utility of targeted next-generation sequencing and immunohistochemistry panels as a screening platform to select targeted therapy for advanced gastric cancer

  2017cites this paper
• Downregulation of DNA methyltransferase 3 alpha promotes cell proliferation and invasion of ectopic endometrial stromal cells in adenomyosis.

  2017cites this paper
• Chapter 15 – Vemurafenib

  2017cites this paper
• Targeting B-RAF Mutated Sarcomas

  2017influential citation
• Targeting BRAF in metastatic colorectal cancer: Maximizing molecular approaches.

  2017cites this paper
• Analysis of the effects of metformin administered alone or in combined treatments in colorectal cancer

  2017cites this paper
• A Phase Ib Dose-Escalation Study of Encorafenib and Cetuximab with or without Alpelisib in Metastatic BRAF-Mutant Colorectal Cancer.

  2017cites this paper
• RAS and RAF mutation status in the selection of patients for anti-EGFR therapy

  2016cites this paper
• SK3/TRPC1/Orai1 complex regulates SOCE-dependent colon cancer cell migration: a novel opportunity to modulate anti-EGFR mAb action by the alkyl-lipid Ohmline

  2016cites this paper
• Advances in targeted and immunobased therapies for colorectal cancer in the genomic era

  2016influential citation
• LY3009120, a panRAF inhibitor, has significant anti-tumor activity in BRAF and KRAS mutant preclinical models of colorectal cancer

  2016cites this paper
• Targeting the serrated pathway of colorectal cancer with mutation in BRAF.

  2016cites this paper
• Genotyping of colorectal cancer for cancer precision medicine: Results from the IPH Center for Molecular Pathology

  2016cites this paper
• Development and clinical application of an integrative genomic approach to personalized cancer therapy

  2016cites this paper
• Reactivation of ERK and Akt confers resistance of mutant BRAF colon cancer cells to the HSP90 inhibitor AUY922

  2016cites this paper
• Tumor cell resistance to antiangiogenic receptor tyrosine kinase inhibitors

  2016cites this paper